Subdermal Implants for Men
Studies have found that men are interested in taking more responsibility for family planning; an implant for men is the Council's lead product in male contraception.
Studies have shown that:
- Men are interested in contraceptive options other than the condom, vasectomy, and withdrawal; and
- Women would welcome additional male contraceptive methods.
The Population Council has clinically evaluated the male contraceptive and hormone replacement effects of prolonged delivery of the synthetic androgen MENT® from subdermal implants.
MENT was identified as a suitable candidate for these indications because it suppresses gonadotropin secretion, which leads to suppression of testosterone and sperm production in the testes. At the same time, MENT replaces testosterone to maintain primary and secondary sex characteristics. MENT has an added advantage in that it does not overstimulate the prostate.
Because MENT is ten times as potent as testosterone, the doses required are lower than those of commercially available testosterone preparations, making it feasible to administer the compound via long-acting subdermal implants. A study in hypogonadal men showed that two MENT implants may provide adequate replacement therapy for most androgen-dependent functions. There was evidence to support selective sparing of the prostate gland.
Several reports indicate that a combination of a synthetic progestin, such as levonorgestrel, and an androgen may be an effective approach for male contraception. Therefore, following completion of a dose-finding study comparing three doses of implants releasing MENT alone, the decision was taken to design a study comparing MENT alone with three MENT-plus-levonorgestrel dose combinations.
A clinical trial to evaluate this approach (using MENT implants in combination with levonorgestrel-releasing Jadelle® implants) was conducted at International Committee for Contraception Research sites in Los Angeles; Münster, Germany; and Santiago, Chile, and is close to completion. A second study was initiated to compare the effects of MENT combined with a progestin implant (Implanon®) with testosterone pellets combined with Implanon.
A clinical trial of 7α-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men (abstract)
von Eckardstein,Sigrid; Noe,Gabriela; Brache,Vivian; Nieschlag,Eberhard; Croxatto,Horacio B.; Alvarez-Sanchez,Francisco; Moo-Young,Alfred J.; Sivin,Irving; Kumar,Narender; Small,Margaret; Sundaram,Kalyan; Population Council International Committee for Contraception Research
Journal of Clinical Endocrinology and Metabolism 88(11): 5232-5239
Publication date: 2003
Evidence for tissue selectivity of the synthetic androgen 7α-methyl-19-nortestosterone in hypogonadal men (abstract) (PDF)
Anderson,Richard A.; Wallace,A.Michael; Sattar,Naveed; Kumar,Narender; Sundaram,Kalyan
Journal of Clinical Endocrinology and Metabolism 88(6): 2784-2793
Publication date: 2003
Technologies for men
Duration: 1/2005 - ongoing
Christina Wang (University of California, Los Angeles)
David T. Baird (MRC Reproductive Biology Unit)
Eberhard Nieschlag (University of Munster, Germany)
Horacio Croxatto (ICMER)
Richard Anderson (MRC Reproductive Biology Unit)